TABLE 1.
Overexpression of miR-24, miR-30b, and miR-142-3p during differentiation maintains CDw93 expression
| Culture | CDw93 (% +) |
CD45 (% +) |
CD1a (% +) |
CD209 (% +) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mφ | DC | Mφ | DC | Mφ | DC | Mφ | DC | |||||||||
| Untreated | 4.6 | ns | 3.7 | ns | 92.0 | ns | 96.0 | ns | 0.0 | ns | 94.1 | ns | 0.0 | ns | 97.3 | ns |
| Control mimic | 5.0 | ns | 5.8 | ns | 96.2 | ns | 98.3 | ns | 0.0 | ns | 96.3 | ns | 0.0 | ns | 92.5 | ns |
| miR-24 mimic | 29.2 | * | 20.8 | * | 92.9 | ns | 97.4 | ns | 0.0 | ns | 91.6 | ns | 0.0 | ns | 91.8 | ns |
| miR-24 inhibitor | 4.8 | ns | 4.3 | ns | 97.8 | ns | 98.0 | ns | 0.0 | ns | 93.3 | ns | 0.0 | ns | 95.5 | ns |
| miR-30b mimic | 30.5 | ** | 20.5 | * | 93.7 | ns | 99.3 | ns | 0.0 | ns | 91.0 | ns | 0.0 | ns | 95.0 | ns |
| miR-30b inhibitor | 5.5 | ns | 7.3 | ns | 95.7 | ns | 97.0 | ns | 0.0 | ns | 93.8 | ns | 0.0 | ns | 93.5 | ns |
| miR-101-3p mimic | 1.8 | ns | 7.9 | ns | 96.3 | ns | 94.4 | ns | 0.0 | ns | 88.7 | ns | 0.0 | ns | 96.2 | ns |
| miR-101-3p inhibitor | 6.0 | ns | 3.8 | ns | 99.0 | ns | 97.2 | ns | 0.0 | ns | 94.5 | ns | 0.0 | ns | 94.5 | ns |
| miR-142-3p mimic | 30.9 | * | 21.0 | * | 96.9 | ns | 98.7 | ns | 0.0 | ns | 90.5 | ns | 0.0 | ns | 93.0 | ns |
| miR-142-3p inhibitor | 4.8 | ns | 6.5 | ns | 95.4 | ns | 95.0 | ns | 0.0 | ns | 92.0 | ns | 0.0 | ns | 95.0 | ns |
| miR-652-3p mimic | 4.9 | ns | 4.1 | ns | 97.0 | ns | 96.5 | ns | 0.0 | ns | 93.1 | ns | 0.0 | ns | 94.9 | ns |
| miR-652-3p inhibitor | 8.7 | ns | 3.7 | ns | 95.6 | ns | 95.6 | ns | 0.0 | ns | 92.7 | ns | 0.0 | ns | 94.8 | ns |
| miR-652-5p mimic | 1.8 | ns | 8.6 | ns | 93.9 | ns | 93.1 | ns | 0.0 | ns | 84.5 | ns | 0.0 | ns | 91.3 | ns |
| miR-652-5p inhibitor | 2.5 | ns | 8.4 | ns | 92.2 | ns | 97.8 | ns | 0.0 | ns | 85.7 | ns | 0.0 | ns | 98.4 | ns |
| miR-1275 mimic | 8.1 | ns | 5.5 | ns | 91.8 | ns | 96.6 | ns | 0.0 | ns | 91.2 | ns | 0.0 | ns | 96.0 | ns |
| miR-1275 inhibitor | 6.8 | ns | 3.9 | ns | 96.8 | ns | 93.6 | ns | 0.0 | ns | 85.9 | ns | 0.0 | ns | 91.8 | ns |
| miR-3656 mimic | 6.8 | ns | 5.9 | ns | 92.5 | ns | 94.3 | ns | 0.0 | ns | 91.4 | ns | 0.0 | ns | 91.0 | ns |
| miR-3656 inhibitor | 6.9 | ns | 1.6 | ns | 97.7 | ns | 92.9 | ns | 0.0 | ns | 95.2 | ns | 0.0 | ns | 94.0 | ns |
| miR-4279 mimic | 5.3 | ns | 1.7 | ns | 99 | ns | 95.5 | ns | 0 | ns | 96.8 | ns | 0 | ns | 95.1 | ns |
| miR-4279 inhibitor | 5.2 | ns | 2.4 | ns | 96.0 | ns | 96.2 | ns | 0.0 | ns | 92.5 | ns | 0.0 | ns | 96.1 | ns |
mD-Mφ and mD-DC cultures were transfected on day 3 and analyzed by flow cytometry for CDw93, CD45, CD1a, and CD209 expression on day 7. Data are presented as means from 5 biologic donors.
*
P < 0.05 is considered significant; **P < 0.005; ns, not significant.